Ability of C-reactive protein to complement multiple prognostic classifiers in men with metastatic castration resistant prostate cancer receiving docetaxel-based chemotherapy

BJU International

Volumn 110, Issue 11 B, 2012, Pages

  Pond, Gregory R ^a   Armstrong, Andrew J ^b   Wood, Brian A ^c   Leopold, Lance ^c   Galsky, Matthew D ^d   Sonpavde, Guru ^e,f  

^a MCMASTER UNIVERSITY   (Canada)

^b DUKE CANCER INSTITUTE   (United States)

^c Ascenta Therapeutics   (United States)

^d Mt Sinai Tisch Cancer Institute   (United States)

^e BAYLOR COLLEGE OF MEDICINE   (United States)

^f Developmental Therapeutics Committee and Co Chair of the Genitourinary Committee   (United States)

Author keywords

C reactive protein; Docetaxel; Metastatic castration resistant prostate cancer; Nomogram; PCWG 2 clinical subtypes; Risk groups

Indexed keywords

ALBUMIN; ALKALINE PHOSPHATASE; C REACTIVE PROTEIN; DOCETAXEL; HEMOGLOBIN; ISOSORBIDE; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; ANTINEOPLASTIC AGENT; RADIOSENSITIZING AGENT; TAXOID; TUMOR MARKER;

ARTICLE; BONE METASTASIS; CANCER PAIN; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CONTROLLED STUDY; GLEASON SCORE; HUMAN; LIVER METASTASIS; LYMPH NODE METASTASIS; MALE; METASTASIS POTENTIAL; NOMOGRAM; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SOFT TISSUE METASTASIS; VISCERAL METASTASIS; BLOOD; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; DISEASE FREE SURVIVAL; DOSE RESPONSE; METABOLISM; METASTASIS; MULTICENTER STUDY; ORCHIECTOMY; PROSPECTIVE STUDY; PROSTATE TUMOR; RANDOMIZED CONTROLLED TRIAL;

ANTINEOPLASTIC AGENTS; C-REACTIVE PROTEIN; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MALE; ORCHIECTOMY; PROGNOSIS; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS; RADIATION-SENSITIZING AGENTS; TAXOIDS; TUMOR MARKERS, BIOLOGICAL;

MLCS; MLOWN;

EID: 84876448534     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2012.11148.x     Document Type: Article

References (36)

1. Tannock IF, de Wit R, Berry WR et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004 ; 351 : 1502-12
2. Berthold DR, Pond GR, Soban F, de Wit R, Eisenberger M, Tannock IF. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol 2008 ; 26 : 242-5
3. Petrylak DP, Tangen CM, Hussain MH et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004 ; 351 : 1513-20
4. Armstrong AJ, Garrett-Mayer ES, Yang YC, de Wit R, Tannock IF, Eisenberger M. A contemporary prognostic nomogram for men with hormonerefractory metastatic prostate cancer: a TAX327 study analysis. Clin Cancer Res 2007 ; 13 : 6396-403
5. Smaletz O, Scher HI, Small EJ et al. Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration. J Clin Oncol 2002 ; 20 : 3972-82
6. Halabi S, Small EJ, Kantoff PW et al. Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol 2003 ; 21 : 1232-7
7. Armstrong AJ, Tannock IF, de Wit R, George DJ, Eisenberger M, Halabi S. The development of risk groups in men with metastatic castration-resistant prostate cancer based on risk factors for PSA decline and survival. Eur J Cancer 2010 ; 46 : 517-25
8. Scher HI, Halabi S, Tannock I et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 2008 ; 26 : 1148-59
9. Beer TM, Lalani AS, Lee S et al. C-reactive protein as a prognostic marker for men with androgenindependent prostate cancer: results from the ASCENT trial. Cancer 2008 ; 112 : 2377-83
10. Prins RC, Rademacher BL, Mongoue- Tchokote S et al. C-reactive protein as an adverse prognostic marker for men with castration-resistant prostate cancer (CRPC): confirmatory results. Urol Oncol 2010 ; 30 : 33-7
11. Sonpavde G, Matveev V, Burke J et al. Randomized Phase II trial of docetaxel plus prednisone in combination with placebo or AT-101, an oral small molecule bcl-2 family antagonist, as first-line therapy for metastatic castration-resistant prostate cancer. J Clin Oncol 2011 ; Nov 29 [ Epub ahead of print ]
12. Gonen M, Heller G. Concordance probability and discriminatory power in proportional hazards regression. Biometrika 2005 ; 92 : 965-70
13. Halabi S, Vogelzang NJ, Kornblith AB et al. Pain predicts overall survival in men with metastatic castrationrefractory prostate cancer. J Clin Oncol 2008 ; 26 : 2544-9
14. Scher HI, Heller G, Molina A et al. Evaluation of circulating tumor cell (CTC) enumeration as an efficacy response biomarker of overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC): planned final analysis (FA) of COU-AA-301, a randomized double-blind, placebo-controlled phase III study of abiraterone acetate (AA) plus low-dose prednisone (P) post docetaxel. J Clin Oncol 2011 ; 29 ( Suppl .): LBA4517
15. Pepys MB, Hirschfield GM. C-reactive protein: a critical update. J Clin Invest 2003 ; 111 : 1805-12
16. Du Clos TW. Function of C-reactive protein. Ann Med 2000 ; 32 : 274-8
17. Thomas-Rudolph D, Du Clos TW, Snapper CM, Mold C. C-reactive protein enhances immunity to Streptococcus pneumoniae by targeting uptake to Fc gamma R on dendritic cells. J Immunol 2007 ; 178 : 7283-91
18. De Marzo AM, Marchi VL, Epstein JI, Nelson WG. Proliferative inflammatory atrophy of the prostate: implications for prostatic carcinogenesis. Am J Pathol 1999 ; 155 : 1985-92
19. Dennis LK, Lynch CF, Torner JC. Epidemiologic association between prostatitis and prostate cancer. Urology 2002 ; 60 : 78-83
20. Tartour E, Dorval T, Mosseri V et al. Serum interleukin 6 and C-reactive protein levels correlate with resistance to IL-2 therapy and poor survival in melanoma patients. Br J Cancer 1994 ; 69 : 911-3
21. Nozoe T, Matsumata T, Kitamura M, Sugimachi K. Significance of preoperative elevation of serum C-reactive protein as an indicator for prognosis in colorectal cancer. Am J Surg 1998 ; 176 : 335-8
22. Legouffe E, Rodriguez C, Picot MC et al. C-reactive protein serum level is a valuable and simple prognostic marker in non Hodgkin ' s lymphoma. Leuk Lymphoma 1998 ; 31 : 351-7
23. Nozoe T, Saeki H, Sugimachi K. Significance of preoperative elevation of serum C-reactive protein as an indicator of prognosis in esophageal carcinoma. Am J Surg 2001 ; 182 : 197-201
24. Polterauer S, Grimm C, Tempfer C et al. C-reactive protein is a prognostic parameter in patients with cervical cancer. Gynecol Oncol 2007 ; 107 : 114-7
25. Schmid M, Schneitter A, Hinterberger S, Seeber J, Reinthaller A, Hefler L. Association of elevated C-reactive protein levels with an impaired prognosis in patients with surgically treated endometrial cancer. Obstet Gynecol 2007 ; 110 : 1231-6
26. Hefler LA, Concin N, Hofstetter G et al. Serum C-reactive protein as independent prognostic variable in patients with ovarian cancer. Clin Cancer Res 2008 ; 14 : 710-4
27. Tatokoro M, Saito K, Iimura Y, Fujii Y, Kawakami S, Kihara K. Prognostic impact of postoperative C-reactive protein level in patients with metastatic renal cell carcinoma undergoing cytoreductive nephrectomy. J Urol 2008 ; 180 : 515-9
28. Yang J, Wezeman M, Zhang X et al. Human C-reactive protein binds activating Fcgamma receptors and protects myeloma tumor cells from apoptosis. Cancer Cell 2007 ; 12 : 252-65
29. Albert MA, Danielson E, Rifai N, Ridker PM. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA 2001 ; 286 : 64-70
30. Ridker PM, Danielson E, Fonseca FA et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008 ; 359 : 2195-207
31. Vigushin DM, Pepys MB, Hawkins PN. Metabolic and scintigraphic studies of radioiodinated human C-reactive protein in health and disease. J Clin Invest 1993 ; 91 : 1351-7
32. de Bono JS, Logothetis CJ, Molina A et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011 ; 364 : 1995-2005
33. Kantoff PW, Higano CS, Shore ND et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010 ; 363 : 411-22
34. de Bono JS, Oudard S, Ozguroglu M et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010 ; 376 : 1147-54
35. de Bono JS, Scher HI, Montgomery RB et al. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res 2008 ; 14 : 6302-9
36. Danila DC, Heller G, Gignac GA et al. Circulating tumor cell number and prognosis in progressive castrationresistant prostate cancer. Clin Cancer Res 2007 ; 13 : 7053-8